Yingbin Fu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yingbin Fu has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Alyssia Lambert
Department of Chemistry, University of Utah, Salt Lake City, UT, USA
3 shared publicationsJon Rainier
Department of Chemistry, University of Utah, Salt Lake City, UT, USA
3 shared publications- Sandeep Kumar
Department of Ophthalmology, Baylor College of Medicine, Houston, TX, USA
3 shared publications - Yannis Mantas Paulus
Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, USA
3 shared publications - Zhao Zhang
Cullen Eye Institute, Baylor College of Medicine, Houston, TX 77030, USA
3 shared publications Alex Jones
Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, Utah
2 shared publications
Latest Publications
- Open Access
- 21 February 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (3) , 252
Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization
Despite extensive use of intravitreal anti-vascular endothelial growth factor (anti-VEGF) biologics for over a decade, neovascular age-related macular degeneration (nAMD) or choroidal neovascularization (CNV) continues to be a major cause of irreversible vision loss in developed countries. Many nAMD patients demonstrate persistent disease activity or experience declining responses over time despite anti-VEGF treatment. The underlying mechanisms of anti-VEGF resistance are poorly understood, and no effective treatment strategies are available to date. Here we review evidence from animal models and clinical studies that supports the roles of neovascular remodeling and arteriolar CNV formation in anti-VEGF resistance. Cholesterol dysregulation, inflammation, and ensuing macrophage activation are critically involved in arteriolar CNV formation and anti-VEGF resistance. Combination therapy by neutralizing VEGF and enhancing cholesterol removal from macrophages is a promising strategy to combat anti-VEGF resistance in CNV.
- 21 February 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (3) , 252
Open AccessTreatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization
Despite extensive use of intravitreal anti-vascular endothelial growth factor (anti-VEGF) biologics for over a decade, neovascular age-related macular degeneration (nAMD) or choroidal neovascularization (CNV) continues to be a major cause of irreversible vision loss in developed countries. Many nAMD patients demonstrate persistent disease activity or experience declining responses over time despite anti-VEGF treatment. The underlying mechanisms of anti-VEGF resistance are poorly understood, and no effective treatment strategies are available to date. Here we review evidence from animal models and clinical studies that supports the roles of neovascular remodeling and arteriolar CNV formation in anti-VEGF resistance. Cholesterol dysregulation, inflammation, and ensuing macrophage activation are critically involved in arteriolar CNV formation and anti-VEGF resistance. Combination therapy by neutralizing VEGF and enhancing cholesterol removal from macrophages is a promising strategy to combat anti-VEGF resistance in CNV.
- Open Access
- 1 February 2024
- Published by MDPI AG in Preprints.org
Treatment Strategies for Anti-vegf Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization
Despite extensive use of intravitreal anti-vascular endothelial growth factor (anti-VEGF) biologics for over a decade, neovascular age-related macular degeneration (nAMD) or choroidal neovascularization (CNV) continues to be a major cause of irreversible vision loss in developed countries. Many nAMD patients demonstrate persistent disease activity or experience declined responses over time despite anti-VEGF treatment. The underlying mechanisms of anti-VEGF resistance are poorly understood, and no effective treatment strategies are available to date. Here we review evidence from animal models and clinical studies that supports the roles of neovascular remodeling and arteriolar CNV formation in anti-VEGF resistance. Cholesterol dysregulation, inflammation, and ensuing macrophage activation are critically involved in arteriolar CNV formation and anti-VEGF resistance. Combination therapy by neutralizing VEGF and enhancing cholesterol removal from macrophages is a promising strategy to combat anti-VEGF resistance in CNV.
- 1 February 2024
- Published by MDPI AG in Preprints.org
Open AccessTreatment Strategies for Anti-vegf Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization
Despite extensive use of intravitreal anti-vascular endothelial growth factor (anti-VEGF) biologics for over a decade, neovascular age-related macular degeneration (nAMD) or choroidal neovascularization (CNV) continues to be a major cause of irreversible vision loss in developed countries. Many nAMD patients demonstrate persistent disease activity or experience declined responses over time despite anti-VEGF treatment. The underlying mechanisms of anti-VEGF resistance are poorly understood, and no effective treatment strategies are available to date. Here we review evidence from animal models and clinical studies that supports the roles of neovascular remodeling and arteriolar CNV formation in anti-VEGF resistance. Cholesterol dysregulation, inflammation, and ensuing macrophage activation are critically involved in arteriolar CNV formation and anti-VEGF resistance. Combination therapy by neutralizing VEGF and enhancing cholesterol removal from macrophages is a promising strategy to combat anti-VEGF resistance in CNV.
- 11 August 2023
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 198,p. e65682
Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography
Age-related macular degeneration (AMD) is a leading cause of blindness among older individuals, and its prevalence is rapidly increasing due to the aging population. Choroidal neovascularization (CNV) or wet AMD, which accounts for 10%-20% of all AMD cases, is responsible for an alarming 80%-90% of AMD-related blindness. Current anti-VEGF therapies show suboptimal responses in approximately 50% of patients. Resistance to anti-VEGF treatment in CNV patients is often associated with arteriolar CNV, while responders tend to have capillary CNV. While fluorescein angiography (FA) is commonly used to assess leakage patterns in wet AMD patients and animal models, it does not provide information about CNV vascular morphology (arteriolar CNV vs. capillary CNV). This protocol introduces the use of indocyanine green angiography (ICGA) to characterize lesion types in laser-induced CNV mouse models. This method is crucial for investigating the mechanisms and treatment strategies for anti-VEGF resistance in wet AMD. It is recommended to incorporate ICGA alongside FA for comprehensive assessment of both leakage and vascular features of CNV in mechanistic and therapeutic studies.
- 11 August 2023
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 198,p. e65682
Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography
Age-related macular degeneration (AMD) is a leading cause of blindness among older individuals, and its prevalence is rapidly increasing due to the aging population. Choroidal neovascularization (CNV) or wet AMD, which accounts for 10%-20% of all AMD cases, is responsible for an alarming 80%-90% of AMD-related blindness. Current anti-VEGF therapies show suboptimal responses in approximately 50% of patients. Resistance to anti-VEGF treatment in CNV patients is often associated with arteriolar CNV, while responders tend to have capillary CNV. While fluorescein angiography (FA) is commonly used to assess leakage patterns in wet AMD patients and animal models, it does not provide information about CNV vascular morphology (arteriolar CNV vs. capillary CNV). This protocol introduces the use of indocyanine green angiography (ICGA) to characterize lesion types in laser-induced CNV mouse models. This method is crucial for investigating the mechanisms and treatment strategies for anti-VEGF resistance in wet AMD. It is recommended to incorporate ICGA alongside FA for comprehensive assessment of both leakage and vascular features of CNV in mechanistic and therapeutic studies.
- Open Access
- 1 November 2022
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 63 (12) , 2
Combination of AIBP, apoA-I, and Aflibercept Overcomes Anti-VEGF Resistance in Neovascular AMD by Inhibiting Arteriolar Choroidal Neovascularization
Purpose: Anti-VEGF resistance represents a major unmet clinical need in the management of choroidal neovascularization (CNV). We have previously reported that a combination of AIBP, apoA-I, and an anti-VEGF antibody overcomes anti-VEGF resistance in laser-induced CNV in old mice in prevention experiments. The purpose of this work is to conduct a more clinically relevant study to assess the efficacy of the combination of AIBP, apoA-I, and aflibercept in the treatment of anti-VEGF resistance of experimental CNV at different time points after laser photocoagulation. Methods: To understand the pathobiology of anti-VEGF resistance, we performed comprehensive examinations of the vascular morphology of laser-induced CNV in young mice that are highly responsive to anti-VEGF treatment, and in old mice that are resistant to anti-VEGF therapy by indocyanine green angiography (ICGA), fluorescein angiography (FA), optical coherence tomography (OCT), and Alexa 568 isolectin labeled choroid flatmounts. We examined the efficacy of the combination therapy of AIBP, apoA-I, and aflibercept intravitreally delivered at 2, 4, and 7 days after laser photocoagulation in the treatment of CNV in old mice. Results: Laser-induced CNV in young and old mice exhibited cardinal features of capillary and arteriolar CNV, respectively. The combination therapy and the aflibercept monotherapy were equally effective in treating capillary CNV in young mice. In old mice, the combination therapy was effective in treating anti-VEGF resistance by potently inhibiting arteriolar CNV, whereas aflibercept monotherapy was ineffective. Conclusions: Combination therapy of AIBP, apoA-I, and aflibercept overcomes anti-VEGF resistance in experimental CNV in old mice by inhibiting arteriolar CNV.
- 1 November 2022
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 63 (12) , 2
Open AccessCombination of AIBP, apoA-I, and Aflibercept Overcomes Anti-VEGF Resistance in Neovascular AMD by Inhibiting Arteriolar Choroidal Neovascularization
Purpose: Anti-VEGF resistance represents a major unmet clinical need in the management of choroidal neovascularization (CNV). We have previously reported that a combination of AIBP, apoA-I, and an anti-VEGF antibody overcomes anti-VEGF resistance in laser-induced CNV in old mice in prevention experiments. The purpose of this work is to conduct a more clinically relevant study to assess the efficacy of the combination of AIBP, apoA-I, and aflibercept in the treatment of anti-VEGF resistance of experimental CNV at different time points after laser photocoagulation. Methods: To understand the pathobiology of anti-VEGF resistance, we performed comprehensive examinations of the vascular morphology of laser-induced CNV in young mice that are highly responsive to anti-VEGF treatment, and in old mice that are resistant to anti-VEGF therapy by indocyanine green angiography (ICGA), fluorescein angiography (FA), optical coherence tomography (OCT), and Alexa 568 isolectin labeled choroid flatmounts. We examined the efficacy of the combination therapy of AIBP, apoA-I, and aflibercept intravitreally delivered at 2, 4, and 7 days after laser photocoagulation in the treatment of CNV in old mice. Results: Laser-induced CNV in young and old mice exhibited cardinal features of capillary and arteriolar CNV, respectively. The combination therapy and the aflibercept monotherapy were equally effective in treating capillary CNV in young mice. In old mice, the combination therapy was effective in treating anti-VEGF resistance by potently inhibiting arteriolar CNV, whereas aflibercept monotherapy was ineffective. Conclusions: Combination therapy of AIBP, apoA-I, and aflibercept overcomes anti-VEGF resistance in experimental CNV in old mice by inhibiting arteriolar CNV.
- 13 August 2022
- Published by Elsevier in Experimental Eye Research
- Vol. 223, 109215
Age differential response to bevacizumab therapy in choroidal neovascularization in rabbits
- 13 August 2022
- Published by Elsevier in Experimental Eye Research
- Vol. 223, 109215
Age differential response to bevacizumab therapy in choroidal neovascularization in rabbits
- Open Access
- 23 February 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (9)
Visual pigment–deficient cones survive and mediate visual signaling despite the lack of outer segments
Significance: The study of visual pigments (rhodopsin in rods and cone opsins in cones) in vision has a long and illustrious history. It is well established that rhodopsin is required for rod phototransduction, outer segment formation, and rod viability. It is not known if the same is true for the cones. By using the cone opsin–deficient mice, we made the surprising observation that cones survive for at least 12 mo without cone opsins, suggesting that cone opsins are dispensable for cone viability. Furthermore, cone opsin–deficient cones continue to mediate visual signaling by relaying the rod signal through rod–cone gap junctions. Our finding represents a major difference between the two types of photoreceptors in vertebrates: rods and cones.
- 23 February 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (9)
Open AccessVisual pigment–deficient cones survive and mediate visual signaling despite the lack of outer segments
Significance: The study of visual pigments (rhodopsin in rods and cone opsins in cones) in vision has a long and illustrious history. It is well established that rhodopsin is required for rod phototransduction, outer segment formation, and rod viability. It is not known if the same is true for the cones. By using the cone opsin–deficient mice, we made the surprising observation that cones survive for at least 12 mo without cone opsins, suggesting that cone opsins are dispensable for cone viability. Furthermore, cone opsin–deficient cones continue to mediate visual signaling by relaying the rod signal through rod–cone gap junctions. Our finding represents a major difference between the two types of photoreceptors in vertebrates: rods and cones.
- 19 February 2021
- Published by Springer Nature
- p. 61-71
Current Understanding of Polypoidal Choroidal Vasculopathy
- 19 February 2021
- Published by Springer Nature
- p. 61-71
Current Understanding of Polypoidal Choroidal Vasculopathy
- 18 February 2020
- Published by Elsevier in The American Journal of Pathology
- Vol. 190 (5) , 1059-1067
Deletion of M-Opsin Prevents M Cone Degeneration in a Mouse Model of Leber Congenital Amaurosis
- 18 February 2020
- Published by Elsevier in The American Journal of Pathology
- Vol. 190 (5) , 1059-1067
Deletion of M-Opsin Prevents M Cone Degeneration in a Mouse Model of Leber Congenital Amaurosis
- 22 March 2018
- Published by Springer Nature
- Vol. 1753, 115-128
Disruption of Rhodopsin Dimerization in Mouse Rod Photoreceptors by Synthetic Peptides Targeting Dimer Interface
Synthetic peptides derived from transmembrane segments of G protein-coupled receptors (GPCR) are used to disrupt GPCR dimer interface. This peptide competition technique is an effective approach to map the dimer interface of GPCR and its functional significance. Here we present a technique to deliver synthetic transmembrane peptides to living mouse rod photoreceptors to disrupt rhodopsin (a prototypical member of Class A GPCRs) dimer formation in the endoplasmic reticulum (ER). We have shown that rhodopsin helix H1- or H8-peptide caused mislocalization of rhodopsin to the perinuclear endoplasmic reticulum (ER).
- 22 March 2018
- Published by Springer Nature
- Vol. 1753, 115-128
Disruption of Rhodopsin Dimerization in Mouse Rod Photoreceptors by Synthetic Peptides Targeting Dimer Interface
Synthetic peptides derived from transmembrane segments of G protein-coupled receptors (GPCR) are used to disrupt GPCR dimer interface. This peptide competition technique is an effective approach to map the dimer interface of GPCR and its functional significance. Here we present a technique to deliver synthetic transmembrane peptides to living mouse rod photoreceptors to disrupt rhodopsin (a prototypical member of Class A GPCRs) dimer formation in the endoplasmic reticulum (ER). We have shown that rhodopsin helix H1- or H8-peptide caused mislocalization of rhodopsin to the perinuclear endoplasmic reticulum (ER).
- 1 December 2017
- Published by Elsevier in The American Journal of Pathology
- Vol. 187 (12) , 2841-2857
Proteolytic Degradation and Inflammation Play Critical Roles in Polypoidal Choroidal Vasculopathy
- 1 December 2017
- Published by Elsevier in The American Journal of Pathology
- Vol. 187 (12) , 2841-2857
Proteolytic Degradation and Inflammation Play Critical Roles in Polypoidal Choroidal Vasculopathy